At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Comparison of Type 2 Diabetes Pharmacotherapy Regimens Using Targeted Learning
In Brief
An observational study evaluating SU, DPP4, and 12 other interventions for Type 2 Diabetes Mellitus and Cardiovascular Diseases. Completed, enrolled 241,981 participants across 6 sites.
Detailed Summary
This study is designed to help patients with type 2 diabetes and their clinicians: (a) identify which glucose lowering medications have the most favorable effects on heart health and other patient-important outcomes, (b) inform the timing of medication initiation, and (c) identify whether medication benefits apply equally to all adults with type 2 diabetes, or may be different based on age, sex, race/ethnicity, baseline heart health status, baseline renal function, or other factors.
Study Details
Timeline
Interventions
Exposure to the class of drugs known as Sulfonylureas (SU)
Exposure to the class of drugs known as Dipeptidyl peptidase-4 inhibitors (DPP4)
Exposure to the class of drugs known as Sodium-glucose cotransporter-2 inhibitors (SGLT2i)
Exposure to the class of drugs known as Glucagon-like peptide-1 receptor agonists (GLP-1RA)
Exposure to either SGLT2i or GLP-1RA
Exposure to agent Linagliptin (DPP4)
Exposure to agent Exenatide (GLP1-RA)
Exposure to agent Liraglutide (GLP-1RA)
Exposure to agent Empagliflozin (SGLT2i)
Exposure to agent Glimepiride (SU)
Exposure to Glimepiride (SU)
Exposure to agent Glimepiride (SU) or Glipizide (SU)
Exposure to either SU or DPP4 excluding Saxagliptin and Alogliptin
Exposure to either Exenatide (GLP-1RA) or Liraglutide (GLP-1RA)